Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)PRNewsWire • 08/31/23
MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud LawsuitPRNewsWire • 08/30/23
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing OperationsPRNewsWire • 08/30/23
NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)Business Wire • 08/28/23